• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule.

作者信息

Yeh J H, Chiu H C

机构信息

Department of Neurology, Shin-Kong WHS Memorial Hospital, Taipei, Taiwan.

出版信息

Acta Neurol Scand. 1999 Mar;99(3):147-51. doi: 10.1111/j.1600-0404.1999.tb07336.x.

DOI:10.1111/j.1600-0404.1999.tb07336.x
PMID:10100957
Abstract

OBJECTIVES

The aim of this study was to compare the efficacy of different protocols of plasmapheresis in the treatment of myasthenia gravis (MG).

MATERIALS AND METHODS

We treated 30 MG patients with plasmapheresis on either a daily or alternately daily schedule for 5 consecutive sessions. Acetylcholine receptor antibody (AchRAb), serum proteins including albumin, globulin, immunoglobulin G (IgG), IgA, and IgM, and MG score were measured before and after the course of plasmapheresis in each group of patients.

RESULTS

The mean percent reductions of serum proteins including IgA (81.5% vs 69.7%), IgM (95.6% vs 87.1%), and globulin (63.2% vs 50.1%) were significantly higher in the daily group. There were no significant differences in AchRAb and IgG levels after treatment between these 2 groups. However, the reduction of MG score was greater in the daily group. All the patients tolerated plasmapheresis well except for 2.7% of them who experienced hypotension.

CONCLUSION

Our results suggest that daily plasmapheresis may be more effective in the treatment of patients with advanced MG.

摘要

相似文献

1
Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule.
Acta Neurol Scand. 1999 Mar;99(3):147-51. doi: 10.1111/j.1600-0404.1999.tb07336.x.
2
Double filtration plasmapheresis in myasthenia gravis--analysis of clinical efficacy and prognostic parameters.
Acta Neurol Scand. 1999 Nov;100(5):305-9. doi: 10.1111/j.1600-0404.1999.tb00401.x.
3
Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis.双重滤过血浆置换与免疫吸附血浆置换治疗重症肌无力患者的比较。
J Neurol. 2000 Jul;247(7):510-3. doi: 10.1007/s004150070149.
4
Optimal volume of processed plasma and total number of selective plasmapheresis sessions in the treatment of patients with severe generalized myasthenia gravis.
J Clin Apher. 1999;14(4):177-80. doi: 10.1002/(sici)1098-1101(1999)14:4<177::aid-jca4>3.0.co;2-l.
5
Pulmonary function study of myasthenia-gravis patients treated with double-filtration plasmapheresis.接受双重过滤血浆置换治疗的重症肌无力患者的肺功能研究。
J Clin Apher. 2003;18(3):125-8. doi: 10.1002/jca.10067.
6
The six year experience of plasmapheresis in patients with myasthenia gravis.重症肌无力患者血浆置换的六年经验
Ther Apher. 2000 Aug;4(4):291-5. doi: 10.1046/j.1526-0968.2000.004004291.x.
7
[Soluble adhesive molecules and cytokines in patients with myasthenia gravis treated with plasmapheresis].[血浆置换治疗的重症肌无力患者中的可溶性黏附分子与细胞因子]
Cas Lek Cesk. 1998 Nov 2;137(21):654-9.
8
Predictors of response to immunomodulation in patients with myasthenia gravis.预测重症肌无力患者对免疫调节治疗的反应。
Muscle Nerve. 2012 May;45(5):648-52. doi: 10.1002/mus.23236.
9
[Immunoadsorption therapy for myasthenia gravis: study on the adsorption capacity of an immunoadsorption column].重症肌无力的免疫吸附治疗:免疫吸附柱吸附容量的研究
J Microbiol Immunol Infect. 1999 Jun;32(2):121-5.
10
Predicting the course of myasthenic weakness following double filtration plasmapheresis.预测双重滤过血浆置换术后肌无力的病程。
Acta Neurol Scand. 2003 Sep;108(3):174-8. doi: 10.1034/j.1600-0404.2003.00107.x.

引用本文的文献

1
Successful Treatment of Incomplete Susac Syndrome with Simultaneous Corticosteroids and Plasmapheresis Followed by Rituximab.同时使用皮质类固醇和血浆置换,随后使用利妥昔单抗成功治疗不完全性苏萨克综合征。
Case Rep Neurol Med. 2021 Aug 12;2021:5591559. doi: 10.1155/2021/5591559. eCollection 2021.
2
Therapeutic Plasma Exchange in Neurologic Diseases: An Experience with 91 Patients in Seven Years.神经疾病中的治疗性血浆置换:七年91例患者的经验
Noro Psikiyatr Ars. 2014 Mar;51(1):63-68. doi: 10.4274/npa.y6879. Epub 2014 Mar 1.
3
Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases.
神经系统疾病患者的治疗性血浆置换:63例病例回顾
Indian J Hematol Blood Transfus. 2017 Mar;33(1):97-105. doi: 10.1007/s12288-016-0661-3. Epub 2016 Feb 22.
4
Current and emerging treatments for the management of myasthenia gravis.目前和新兴的重症肌无力治疗方法。
Ther Clin Risk Manag. 2011;7:313-23. doi: 10.2147/TCRM.S14015. Epub 2011 Jul 22.
5
Immunomodulatory therapies in neurologic critical care.神经危重症中的免疫调节治疗。
Neurocrit Care. 2010 Feb;12(1):132-43. doi: 10.1007/s12028-009-9274-0. Epub 2009 Sep 23.
6
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.血浆置换在加速那他珠单抗清除及恢复白细胞功能方面的作用。
Neurology. 2009 Feb 3;72(5):402-9. doi: 10.1212/01.wnl.0000341766.59028.9d.
7
Plasma exchange for myasthenia gravis.用于重症肌无力的血浆置换
Cochrane Database Syst Rev. 2002;2002(4):CD002275. doi: 10.1002/14651858.CD002275.
8
Advances in myasthenia gravis.重症肌无力的进展
Curr Neurol Neurosci Rep. 2002 Jan;2(1):89-95. doi: 10.1007/s11910-002-0058-6.